Cargando…
Efficacy and Safety of Alitretinoin for Chronic Hand Eczema in Korean Patients
BACKGROUND: Chronic hand eczema (CHE) tends to be refractory to conventional therapy. Previous clinical trials have found that a 24-week treatment course of oral alitretinoin is effective and well tolerated for CHE treatment. OBJECTIVE: The aim of this study was to investigate the efficacy and safet...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Dermatological Association; The Korean Society for Investigative Dermatology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884714/ https://www.ncbi.nlm.nih.gov/pubmed/27274636 http://dx.doi.org/10.5021/ad.2016.28.3.364 |
_version_ | 1782434402698002432 |
---|---|
author | Kwon, Hyoung Il Kim, Jeong Eun Ko, Joo Yeon Ro, Young Suck |
author_facet | Kwon, Hyoung Il Kim, Jeong Eun Ko, Joo Yeon Ro, Young Suck |
author_sort | Kwon, Hyoung Il |
collection | PubMed |
description | BACKGROUND: Chronic hand eczema (CHE) tends to be refractory to conventional therapy. Previous clinical trials have found that a 24-week treatment course of oral alitretinoin is effective and well tolerated for CHE treatment. OBJECTIVE: The aim of this study was to investigate the efficacy and safety of oral alitretinoin in Korean CHE patients. METHODS: A total of 27 patients with moderate to severe CHE took 30 mg of alitretinoin daily for 12 weeks. The primary efficacy parameter was the physician's global assessment (PGA). The response was defined as a patient being "clear" or "almost clear" of disease. The secondary efficacy parameters were the modified total lesion symptom score (mTLSS) and the patients' global assessment (PaGA). All adverse events and laboratory abnormalities were recorded during the treatment period. RESULTS: Alitretinoin led to CHE symptom improvement in 44.4% of patients. The PGA, mTLSS, and PaGA scores correlated well with each other. Reported adverse events were typical retinoid class effects and headache was the most common. CONCLUSION: Taking 30 mg of oral alitretinoin daily for 12 weeks was found to be effective in treating Korean patients with CHE, compared with the 24 week-treatment shown in previous studies. |
format | Online Article Text |
id | pubmed-4884714 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Korean Dermatological Association; The Korean Society for Investigative Dermatology |
record_format | MEDLINE/PubMed |
spelling | pubmed-48847142016-06-03 Efficacy and Safety of Alitretinoin for Chronic Hand Eczema in Korean Patients Kwon, Hyoung Il Kim, Jeong Eun Ko, Joo Yeon Ro, Young Suck Ann Dermatol Original Article BACKGROUND: Chronic hand eczema (CHE) tends to be refractory to conventional therapy. Previous clinical trials have found that a 24-week treatment course of oral alitretinoin is effective and well tolerated for CHE treatment. OBJECTIVE: The aim of this study was to investigate the efficacy and safety of oral alitretinoin in Korean CHE patients. METHODS: A total of 27 patients with moderate to severe CHE took 30 mg of alitretinoin daily for 12 weeks. The primary efficacy parameter was the physician's global assessment (PGA). The response was defined as a patient being "clear" or "almost clear" of disease. The secondary efficacy parameters were the modified total lesion symptom score (mTLSS) and the patients' global assessment (PaGA). All adverse events and laboratory abnormalities were recorded during the treatment period. RESULTS: Alitretinoin led to CHE symptom improvement in 44.4% of patients. The PGA, mTLSS, and PaGA scores correlated well with each other. Reported adverse events were typical retinoid class effects and headache was the most common. CONCLUSION: Taking 30 mg of oral alitretinoin daily for 12 weeks was found to be effective in treating Korean patients with CHE, compared with the 24 week-treatment shown in previous studies. Korean Dermatological Association; The Korean Society for Investigative Dermatology 2016-06 2016-05-25 /pmc/articles/PMC4884714/ /pubmed/27274636 http://dx.doi.org/10.5021/ad.2016.28.3.364 Text en Copyright © 2016 The Korean Dermatological Association and The Korean Society for Investigative Dermatology http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kwon, Hyoung Il Kim, Jeong Eun Ko, Joo Yeon Ro, Young Suck Efficacy and Safety of Alitretinoin for Chronic Hand Eczema in Korean Patients |
title | Efficacy and Safety of Alitretinoin for Chronic Hand Eczema in Korean Patients |
title_full | Efficacy and Safety of Alitretinoin for Chronic Hand Eczema in Korean Patients |
title_fullStr | Efficacy and Safety of Alitretinoin for Chronic Hand Eczema in Korean Patients |
title_full_unstemmed | Efficacy and Safety of Alitretinoin for Chronic Hand Eczema in Korean Patients |
title_short | Efficacy and Safety of Alitretinoin for Chronic Hand Eczema in Korean Patients |
title_sort | efficacy and safety of alitretinoin for chronic hand eczema in korean patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884714/ https://www.ncbi.nlm.nih.gov/pubmed/27274636 http://dx.doi.org/10.5021/ad.2016.28.3.364 |
work_keys_str_mv | AT kwonhyoungil efficacyandsafetyofalitretinoinforchronichandeczemainkoreanpatients AT kimjeongeun efficacyandsafetyofalitretinoinforchronichandeczemainkoreanpatients AT kojooyeon efficacyandsafetyofalitretinoinforchronichandeczemainkoreanpatients AT royoungsuck efficacyandsafetyofalitretinoinforchronichandeczemainkoreanpatients |